<DOC>
	<DOCNO>NCT01665391</DOCNO>
	<brief_summary>The primary objective trial follow : - compare achievement partial remission ( PR ) complete remission ( CR ) urinary protein : creatinine ratio ( Up/c ratio ) patient treat fresolimumab versus placebo - compare safety profile patient treat fresolimumab versus placebo The secondary objective follow : - To compare reduction proteinuria patient treat fresolimumab versus placebo - To evaluate fresolimumab dose-dependent reduction proteinuria - To compare change renal function ( estimate glomerular filtration rate [ eGFR ] ) patient treat fresolimumab versus placebo - To evaluate multiple-dose pharmacokinetics fresolimumab</brief_summary>
	<brief_title>A Study Fresolimumab Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis ( FSGS )</brief_title>
	<detailed_description />
	<mesh_term>Glomerulosclerosis , Focal Segmental</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The patient 's renal biopsy consistent diagnosis primary Focal Segmental Glomerulosclerosis ( FSGS ) include histological subtypes . The patient eGFR ≥ 30 mL/min/1.73 m2 The patient urinary total protein : creatinine ratio ≥ 3 mg protein/mg creatinine In opinion Investigator , patient steroidresistant FSGS . The patient must treat FSGS course highdose steroid therapy minimum 4 week The patient treat ACEi ( angiotensin convert enzyme inhibitor ) and/or ARB ( angiotensin receptor blocker ) stable dose minimum 4 week prior Visit 2 ( treatment start ) The patient FSGS Investigator 's opinion secondary another condition The patient take prednisone dose &gt; 10 mg/day ( equivalent dose alternative glucocorticoid ) within 4 week prior Visit 1 ( Screening Visit ) . The patient receive systemically administer immunosuppressive drug ( glucocorticoid ) within 8 week prior Visit 1 . The patient receive rituximab within 6 month prior Visit 1 . The patient history organ transplantation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>